Jonathan Young, Chief Operating Officer at Akero Therapeutics, Inc. (AKRO), sold 8,710 shares at $26.42 ($232K) on 2024-09-03, disclosed to the SEC on 2024-09-05.
Scheduled sale ($232k) by Chief Operating Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $26.42 | 3,710 | $98K | 42.3% |
| 2 | $26.42 | 3,710 | $98K | 42.3% |
| 3 | $27.58 | 1,290 | $36K | 15.4% |
| Total | $26.59 avg | 8,710 | $232K | 100% |
| Filing → |
| AKRO | SELL | 2025-09-04 | $705K | — | Filing → |
| AKRO | SELL | 2025-08-13 | $1.2M | — | Filing → |
| AKRO | SELL | 2025-06-20 | $159K | — | Filing → |